Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Thermo Fisher Scientific Inc демонстрирует смешанную картину по фундаментальным показателям. С одной стороны, компания имеет высокие значения мультипликаторов, таких как P/E, P/S и P/FCF, что указывает на возможную переоцененность по сравнению с отраслью. С другой стороны, рост прибыли на акцию (EPS) и позитивная динамика по выручке и чистой прибыли свидетельствуют о сильных операционных показателях. Однако, рентабельность (ROE и ROI) ниже медианы, что вызывает опасения по поводу эффективности использования капитала. Долговая нагрузка компании также выше медианных значений, что может представлять собой риск в условиях экономической неопределенности. Дивиденды остаются на низком уровне, что может не удовлетворять инвесторов, ориентированных на доход. Тем не менее, компания показывает хороший рост активов и чистой прибыли, что создает позитивный фон для долгосрочных инвестиций. В целом, учитывая все вышеперечисленные факторы, целесообразно пересмотреть целевую цену с учетом роста мультипликаторов и долговой нагрузки, что может указывать на необходимость более осторожного подхода к оценке компании.

Thermo Fisher Scientific Inc

(RTTNews) - Thermo Fisher Scientific Inc. (TMO), on Monday, announced that it has signed a definitive agreement to sell its microbiology business to Astorg.
The transaction is approximately $1.075 billion, consisting of cash and a $50 million seller note.
The deal is expected to close in the second half of 2026.
The company said the microbiology business provides antimicrobial susceptibility testing and culture media solutions and generated $645 million in revenue in 2025.
Thermo Fisher said the deal is expected to be dilutive to adjusted earnings per share by $0.15 in the first full year following the close.
The company said it will provide further details on the expected impact on its 2026 outlook during its second-quarter earnings call.
In the pre-market trading, Thermo Fisher Scientific is 0.15% lesser at $469 on the New York Stock Exchange.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Thermo Fisher To Sell Microbiology Business To Astorg

The S&P 500 Index ($SPX) (SPY) on Thursday closed down -0.41%, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -0.36%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.57%. June E-mini S&P futures (ESM26) fell -0.42%, and June E-mini Nasdaq futures (NQM26) fell -0.59%.
Stock indexes erased early gains on Thursday and settled lower as peace talks with Iran remain in limbo. The US and Iran are locked in a battle for control of the Strait of Hormuz, with both sides blocking the waterway to gain leverage during an extended ceasefire. The US said it was waiting for a response from Iran before peace talks could restart, and Iran said it will not resume negotiations while a US naval blockade on its ports is in place. Stock losses accelerated on Thursday amid signs the war in Iran will persist after President Trump said a deal with Iran will only be made "when it's appropriate and good" for the US and its allies.
Join 200K+ Subscribers: Find out why the midday Barchart Brief newsletter is a must-read for thousands daily.
Stock index initially moved higher on Thursday, with the S&P 500 and Nasdaq 100 posting new all-time highs amid a rally in chipmakers that boosted the broader market. Texas Instruments rose more than +19% to lead chipmakers higher after reporting strong earnings. Other positive earnings were also supportive of the market, with United Rentals up +22% and Comcast up more than +7% after reporting better-than-expected Q1 revenue. Also, Keurig Dr. Pepper rose more than +7% after reporting stronger-than-expected Q1 net sales.
The weakness in software stocks on Thursday was a negative factor for the broader market, with ServiceNow falling more than -17% after reporting disappointing earnings and saying the war in the Middle East has delayed some sales deals. Also, IBM fell more than -8% after reporting Q1 results that featured an underwhelming read for its software business.
Thursday’s US economic news was mixed for stocks. Weekly initial unemployment claims rose by +6,000 to 214,000, showing a weaker labor market than expectations of 210,000. Also, the Mar Chicago Fed national activity index fell -0.23 to a 4-month low of -0.20, weaker than expectations of -0.13. Conversely, the Apr S&P manufacturing PMI rose +1.7 to 54.0, stronger than expectations of 52.5 and the strongest level in nearly 4 years.
WTI crude oil prices (CLM26) rose more than +3% on Thursday as the Strait of Hormuz remains essentially closed, threatening to deepen the global energy crisis. Gains in crude oil accelerated on Thursday after Axios reported that Iran laid more mines in the Strait of Hormuz this week, and President Trump ordered the US Navy to "shoot and kill" any Iranian boats laying mines with "no hesitation." The ongoing blockade could exacerbate global oil and fuel shortages, as about a fifth of the world’s oil and liquefied natural gas transits through the strait.
Earnings season continues this week. So far, 81% of the 123 S&P 500 companies that reported Q1 earnings have beaten estimates. Q1 S&P 500 earnings are projected to climb +12% y/y, according to Bloomberg Intelligence. Stripping out the technology sector, Q1 earnings are projected to increase around +3%, the weakest in two years.
The markets are discounting a 1% chance for a +25 bp FOMC rate hike at the April 28-29 policy meeting.
Overseas stock markets settled lower on Thursday. The Euro Stoxx 50 fell to a 2-week low and closed down -0.19%. China's Shanghai Composite fell from a 1.25-month high and closed down -0.32%. Japan's Nikkei Stock 225 fell from a record high and closed down -0.75%.
Interest Rates
June 10-year T-notes (ZNM6) on Thursday closed down -7.5 ticks. The 10-year T-note yield rose +1.9 bp to 4.322%. Jun T-notes fell to a 1.5-week low on Thursday, and the 10-year T-note yield rose to a 1.5-week high of 4.349%. Soaring crude oil prices on Thursday pushed inflation expectations higher and weighed on T-notes, as the 10-year breakeven inflation rate rose to a 5-week high of 2.429%. Losses in T-notes were limited after weekly US jobless claims rose more than expected, a dovish factor for Fed policy.
European government bond yields moved higher on Thursday. The 10-year German bund yield rose +0.1 bp to 3.009%. The 10-year UK gilt yield rose to a 3.5-week high of 4.973% and finished up by +2.9 bp to 4.939%.
The Eurozone Apr S&P manufacturing PMI unexpectedly rose +0.6 to 52.2, stronger than expectations of a decline to 50.9 and the fastest pace of expansion in nearly four years. However, the Apr composite PMI fell -2.1 to 48.6, weaker than expectations of 50.1 and the weakest level in 17 months.
Eurozone Mar new car registrations rose +12.5% y/y to 1.158 million units, the biggest increase in nearly two years.
The UK Apr S&P manufacturing PMI unexpectedly rose +2.6 to 53.6, stronger than expectations of a decline to 50.3 and the fastest pace of expansion in nearly four years.
Swaps are discounting a 9% chance of a +25 bp ECB rate hike at its next policy meeting on April 30.
US Stock Movers
ServiceNow (NOW) closed down more than -17% to lead software stocks lower and lead losers in the S&P 500 after cutting its full-year subscription adjusted gross margin forecast to 81.5% from 82%, weaker than the consensus of 82.1%. Also, Workday (WDAY) closed down more than -9% to lead losers in the Nasdaq 100, and Salesforce (CRM) closed down more than -8% to lead losers in the Dow Jones Industrials. In addition, IBM (IBM) and Atlassian (TEAM) closed down more than -8%, and Intuit (INTU), Adobe Systems (ADBE), and Autodesk (ADSK) closed down more than -6%. Finally, Oracle (ORCL) closed down more than -5%, and Microsoft (MSFT) closed down -4%.
Texas Instruments (TXN) closed up more than +19% to lead chipmakers higher and gainers in the Nasdaq 100 after reporting Q1 revenue of $4.83 billion, better than the consensus of $4.53 billion, and forecasting Q2 revenue of $5.00 billion to $5.40 billion, well above the consensus of $4.85 billion. Also, ON Semiconductor (ON) and Microchip Technology (MCHP) closed up more than +9%, and NXP Semiconductors NV (NXPI) closed up more th +6%. In addition, Analog Devices (ADI) and Marvell Technology (MRVL) closed up more than +5%, and ARM Holdings Plc (ARM) closed up more than +3%. Finally, Intel (INTC) closed up more than 2%.
ASGN Inc (ASGN) closed down more than -51% after reporting Q1 revenue of $968.3 million, below the consensus of $972.9 million, and forecasting Q2 revenue of $970 million to $1.00 billion, weaker than the consensus of $1.02 billion.
Medpace Holdings (MEDP) closed down more than -22% after forecasting full-year EPS of $16.68 to $17.50, the midpoint below the consensus of $17.12.
Lululemon Athletica (LULU) closed down more than -13% on disappointment with the naming of Heidi O’Neill as the new CEO, a surprise pick with no previous experience as a CEO.
Thermo Fisher Scientific (TMO) closed down more than -9% after reporting Q1 organic revenue growth of +1.00%, weaker than the consensus of +1.17%.
Las Vegas Sands (LVS) closed down more than -8% after raising its full-year capital expenditure forecast to $1.49 billion from a previous forecast of $1.33 billion, well above the consensus of $1.27 billion.
Tesla (TSLA) closed down more than -3% after boosting its full-year capital expenditure to more than $25 billion to support its push into AI and robotics.
Honeywell International (HON) closed down more than -2% after reporting Q1 sales of $9.14 billion, below the consensus of $9.30 billion.
United Rentals (URI) closed up more than +22% to lead gainers in the S&P 500 after reporting Q1 revenue of $3.99 billion, above the consensus of $3.88 billion, and raising its full-year revenue forecast to $16.9 billion-$17.4 billion from a previous forecast of $16.8 billion-$17.3 billion, stronger than the consensus of $17.07 billion.
West Pharmaceutical Services (WST) closed up more than +12% after reporting Q1 net sales of $844.9 million, well above the consensus of $780.4 million, and raising its full-year net sales forecast to $3.30 billion-$3.35 billion from a previous estimate of $3.22 billion-$3.28 billion, better than the consensus of $3.25 billion.
Comcast (CMCSA) closed up more than +7% after reporting Q1 revenue of $31.46 billion, stronger than the consensus of $30.35 billion.
Keurig Dr. Pepper (KDP) closed up more than +7% after reporting Q1 net sales of $3.98 billion, above the consensus of $3.83 billion.
CSX Corp. (CSX) closed up more than +6% after reporting Q1 operating income of $1.25 billion, higher than the consensus of $1.14 billion.
Hasbro (HAS) closed up more than +6% after reporting preliminary Q1 net revenue of $970 million to $985 million, well above the consensus of $908.6 million.
Earnings Reports(4/24/2026)
Charter Communications Inc (CHTR), First Hawaiian Inc (FHB), Gentex Corp (GNTX), Hasbro Inc (HAS), HCA Healthcare Inc (HCA), Norfolk Southern Corp (NSC), Procter & Gamble Co/The (PG), SLB Ltd (SLB), Southern Copper Corp (SCCO), Western Union Co/The (WU).
On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Stocks Settle Lower on US-Iran Stalemate

The S&P 500 Index ($SPX) (SPY) today is up +0.07%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.05%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.03%. June E-mini S&P futures (ESM26) are up +0.07%, and June E-mini Nasdaq futures (NQM26) are up +0.10%.
Stock indexes recovered from early losses today and are trading slightly higher as a rally in chipmakers gives the broader market a boost. Texas Instruments is up more than +16% to lead chipmakers higher after reporting strong earnings. Other positive earnings results are also liftin stocks, with United Rentals up +20% and Comcast up more than +7% after reporting better-than-expected Q1 revenue. Also, Keurig Dr. Pepper is up more than +6% after reporting stronger-than-expected Q1 net sales.
Join 200K+ Subscribers: Find out why the midday Barchart Brief newsletter is a must-read for thousands daily.
Stock indexes initially moved lower today as peace talks with Iran remain in limbo. The US and Iran are locked in a battle for control of the Strait of Hormuz, with both sides blocking the waterway to gain leverage during an extended ceasefire. The US said it was waiting for a response from Iran before peace talks could restart, and Iran said it will not resume negotiations while a US naval blockade on its ports is in place. Higher crude oil prices are raising inflation expectations and pushing bond yields higher, with the 10-year T-note yield climbing to a 1.5-week high of 4.34%.
The weakness in software stocks is also pressuring the broader market today, with ServiceNow down more than 16% after reporting disappointing earnings and saying the war in the Middle East has delayed some sales deals. Also, IBM is down more than -9% after reporting Q1 results that featured an underwhelming read for its software business.
Today’s US economic news was mixed for stocks. Weekly initial unemployment claims rose by +6,000 to 214,000, showing a weaker labor market than expectations of 210,000. Also, the Mar Chicago Fed national activity index fell -0.23 to a 4-month low of -0.20, weaker than expectations of -0.13. Conversely, the Apr S&P manufacturing PMI rose +1.7 to 54.0, stronger than expectations of 52.5 and the strongest level in nearly 4 years.
WTI crude oil prices (CLM26) are up nearly +1% today as the Strait of Hormuz remains essentially closed, threatening to deepen the global energy crisis. The blockade could exacerbate global oil and fuel shortages, as about a fifth of the world’s oil and liquefied natural gas transits through the strait.
Earnings season continues this week. So far, 79% of the 101 S&P 500 companies that reported Q1 earnings have beaten estimates. Q1 S&P 500 earnings are projected to climb +12% y/y, according to Bloomberg Intelligence. Stripping out the technology sector, Q1 earnings are projected to increase around +3%, the weakest in two years.
The markets are discounting a 1% chance for a +25 bp FOMC rate hike at the April 28-29 policy meeting.
Overseas stock markets are lower today. The Euro Stoxx 50 fell to a 2-week low and is down -0.05%. China's Shanghai Composite fell from a 1.25-month high and closed down -0.32%. Japan's Nikkei Stock 225 fell from a record high and closed down -0.75%.
Interest Rates
June 10-year T-notes (ZNM6) today are down -1 tick. The 10-year T-note yield is up +0.2 bp to 4.305%. Jun T-notes fell to a 1.5-week low today, and the 10-year T-note yield rose to a 1.5-week high of 4.337%. An increase in inflation expectations is weighing on T-notes, as the 10-year breakeven inflation rate rose to a 1-month high of 2.409% today. T-notes recovered most of their losses after weekly US jobless claims rose more than expected, a dovish factor for Fed policy.
European government bond yields are moving higher today. The 10-year German bund yield is up +0.5 bp to 3.013%. The 10-year UK gilt yield rose to a 3.5-week high of 4.973% and is up by +1.0 bp to 4.920%.
The Eurozone Apr S&P manufacturing PMI unexpectedly rose +0.6 to 52.2, stronger than expectations of a decline to 50.9 and the fastest pace of expansion in nearly four years. However, the Apr composite PMI fell -2.1 to 48.6, weaker than expectations of 50.1 and the weakest level in 17 months.
Eurozone Mar new car registrations rose +12.5% y/y to 1.158 million units, the biggest increase in nearly two years.
The UK Apr S&P manufacturing PMI unexpectedly rose +2.6 to 53.6, stronger than expectations of a decline to 50.3 and the fastest pace of expansion in nearly four years.
Swaps are discounting a 10% chance of a +25 bp ECB rate hike at its next policy meeting on April 30.
US Stock Movers
Texas Instruments (TXN) is up more than +16% to lead chipmakers higher and gainers in the Nasdaq 100 after reporting Q1 revenue of $4.83 billion, better than the consensus of $4.53 billion, and forecasting Q2 revenue of $5.00 billion to $5.40 billion, well above the consensus of $4.85 billion. Also, ON Semiconductor (ON) is up more than +9%, and Microchip Technology (MCHP) is up more than +7%. In addition, NXP Semiconductors NV (NXPI) and Analog Devices (ADI) are up more than +6% and Marvell Technology (MRVL) and ARM Holdings Plc (ARM) are more than +4%. Finally, Intel (INTC) is up more than 2%.
ServiceNow (NOW) is down more than -16% to lead software stocks lower and lead losers in the S&P 500 after cutting its full-year subscription adjusted gross margin forecast to 81.5% from 82%, weaker than the consensus of 82.1%. Also, IBM (IBM) is down more than -8% to lead losers in the Dow Jones Industrials, and Workday (WDAY) is down more than -8% to lead losers in the Nasdaq 100. In addition, Atlassian (TEAM) is also down more than -11%, and Salesforce (CRM) is down more than -8%. Finally, Intuit (INTU) and Adobe Systems (ADBE) are down more than -7%, Autodesk (ADSK) is down more than -6%, and Oracle (ORCL) is down more than -4%.
United Rentals (URI) is up more than +20% to lead gainers in the S&P 500 after reporting Q1 revenue of $3.99 billion, above the consensus of $3.88 billion, and raising its full-year revenue forecast to $16.9 billion-$17.4 billion from a previous forecast of $16.8 billion-$17.3 billion, stronger than the consensus of $17.07 billion.
West Pharmaceutical Services (WST) is up more than +12% after reporting Q1 net sales of $844.9 million, well above the consensus of $780.4 million, and raising its full-year net sales forecast to $3.30 billion-$3.35 billion from a previous estimate of $3.22 billion-$3.28 billion, better than the consensus of $3.25 billion.
Hasbro (HAS) is up more than +8% after reporting preliminary Q1 net revenue of $970 million to $985 million, well above the consensus of $908.6 million.
Comcast (CMCSA) is up more than +7% after reporting Q1 revenue of $31.46 billion, stronger than the consensus of $30.35 billion.
Keurig Dr. Pepper (KDP) is up more than +6% after reporting Q1 net sales of $3.98 billion, above the consensus of $3.83 billion.
CSX Corp. (CSX) is up more than +6% after reporting Q1 operating income of $1.25 billion, higher than the consensus of $1.14 billion.
ASGN Inc (ASGN) is down more than -41% after reporting Q1 revenue of $968.3 million, below the consensus of $972.9 million, and forecasting Q2 revenue of $970 million to $1.00 billion, weaker than the consensus of $1.02 billion.
Medpace Holdings (MEDP) is down more than -22% after forecasting full-year EPS of $16.68 to $17.50, the midpoint below the consensus of $17.12.
Lululemon Athletica (LULU) is down more than -11% on disappointment of the naming of Heidi O’Neill as the new CEO, a surprise pick with no previous experience as a CEO.
Thermo Fisher Scientific (TMO) is down more than -8% after reporting Q1 organic revenue growth of +1.00%, weaker than the consensus of +1.17%.
Las Vegas Sands (LVS) is down more than -8% after raising its full-year capital expenditure forecast to $1.49 billion from a previous forecast of $1.33 billion, well above the consensus of $1.27 billion.
Tesla (TSLA) is down more than -2% after boosting its full-year capital expenditure to more than $25 billion to support its push into AI and robotics.
Honeywell International (HON) is down more than -1% after reporting Q1 sales of $9.14 billion, below the consensus of $9.30 billion.
Earnings Reports(4/23/2026)
American Express Co (AXP), Ameriprise Financial Inc (AMP), Baker Hughes Co (BKR), Blackstone Inc (BX), CBRE Group Inc (CBRE), CenterPoint Energy Inc (CNP), Comcast Corp (CMCSA), Comfort Systems USA Inc (FIX), Digital Realty Trust Inc (DLR), Dover Corp (DOV), Dow Inc (DOW), Edwards Lifesciences Corp (EW), Erie Indemnity Co (ERIE), Freeport-McMoRan Inc (FCX), Hartford Insurance Group Inc/The (HIG), Honeywell International Inc (HON), Huntington Bancshares Inc/OH (HBAN), Intel Corp (INTC), Keurig Dr Pepper Inc (KDP), Lockheed Martin Corp (LMT), Nasdaq Inc (NDAQ), Newmont Corp (NEM), NextEra Energy Inc (NEE), PG&E Corp (PCG), Pool Corp (POOL), Principal Financial Group Inc (PFG), PulteGroup Inc (PHM), Roper Technologies Inc (ROP), Snap-on Inc (SNA), Thermo Fisher Scientific Inc (TMO), Union Pacific Corp (UNP), VeriSign Inc (VRSN), West Pharmaceutical Services Inc (WST).
On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Stock Indexes Recover on Strength in Chipmakers

Data is currently not available
Edit My Quotes
Add up to 25 symbols
To add symbols:
Type a symbol or company name. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return.
Copy and paste multiple symbols separated by spaces.
These symbols will be available throughout the site during your session.
Save data
Data is currently not available
Edit My European Quotes
Add up to 25 instruments
To add instruments:
Type a instrument or company name. When the instrument you want to add appears, add it to My European Quotes by selecting it and pressing Enter/Return.
Copy and paste multiple instruments separated by spaces.
These instruments will be available throughout the site during your session.
Save data
Data is currently not available
Your symbols have been updated
You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com.
Continue
Data is currently not available
Edit Watchlist
Add up to 20 symbols
To add symbols:
Type a symbol or company name. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return.
Copy and paste multiple symbols separated by spaces.
These symbols will be available throughout the site during your session.
Save data

Thermo Fisher (TMO) Q1 2026 Earnings Transcript

For the quarter ended March 2026, Thermo Fisher Scientific (TMO) reported revenue of $11.01 billion, up 6.2% over the same period last year. EPS came in at $5.44, compared to $5.15 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $10.83 billion, representing a surprise of +1.62%. The company delivered an EPS surprise of +4.67%, with the consensus EPS estimate being $5.20.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Thermo Fisher performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenue Growth - Organic: 1% compared to the 1.4% average estimate based on four analysts.
Revenues- Laboratory Products and Biopharma Services: $6.04 billion compared to the $5.77 billion average estimate based on four analysts. The reported number represents a change of +7% year over year.
Revenues- Specialty Diagnostics: $1.14 billion versus the four-analyst average estimate of $1.17 billion. The reported number represents a year-over-year change of -0.5%.
Revenues- Life Sciences Solutions: $2.64 billion compared to the $2.56 billion average estimate based on four analysts. The reported number represents a change of +12.6% year over year.
Revenues- Analytical Instruments: $1.72 billion versus the four-analyst average estimate of $1.74 billion. The reported number represents a year-over-year change of -0.1%.
Revenues- Eliminations: $-524 million versus $-481.59 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +8.7% change.
Shares of Thermo Fisher have returned +4.7% over the past month versus the Zacks S&P 500 composite's +9.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Thermo Fisher (TMO) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

GE HealthCare Technologies Inc. GEHC is scheduled to report first-quarter 2026 results on April 29, before market open.
In the last reported quarter, the company’s adjusted earnings per share (EPS) of $1.44 surpassed the Zacks Consensus Estimate by 0.70%. The company beat on earnings in each of the trailing four quarters, delivering an average surprise of 7.52%.
Let’s check out the factors that might have shaped GEHC’s performance prior to the announcement.
GE HealthCare Technologies Inc. Price and EPS Surprise
Factors Likely to Have Driven GEHC’s Q1 Performance
GE HealthCare Technologies’ quarterly results are expected to reflect steady underlying demand, supported by robust developed-market trends and continued momentum in its high-growth Pharmaceutical Diagnostics business.
Following a solid exit to 2025, the company is likely to have sustained low- to mid-single-digit organic revenue growth in the first quarter, supported by a record $21.8 billion backlog that continues to provide revenue visibility. However, this growth may have been partially offset by ongoing weakness in China and the delayed commercial impact of recently launched products awaiting regulatory approval.
At the margin level, profitability is likely to have remained under pressure. While management has executed supply-chain adjustments and productivity initiatives through its “Heartbeat” program, tariff-related costs (previously a significant headwind) are likely to have continued to weigh on earnings, albeit at a moderating pace.
Across segments, Imaging is expected to have delivered stable growth, driven by healthy demand in the U.S. and EMEA markets, particularly in nuclear medicine. However, margins in the segment are likely to have remained under pressure due to tariffs and mix. Advanced Visualization Solutions should have maintained mid-single-digit growth, supported by strong adoption of newer platforms, such as Vivid Pioneer and continued demand across cardiovascular and women’s health.
Patient Care Solutions is likely to reflect sequential improvement following earlier shipment disruptions, although year-over-year performance might have remained muted due to weakness in Life Support Solutions and unfavorable mix dynamics.
Pharmaceutical Diagnostics is expected to have led overall growth, supported by robust demand for contrast media and increasing adoption of radiopharmaceuticals. While Flyrcado remains in the early stages of commercialization, improving delivery consistency and gradual customer onboarding suggest a growing contribution.
GEHC’s Estimate Picture
For first-quarter 2026, the Zacks Consensus Estimate for revenues is pegged at $5.05 billion, implying an improvement of 5.8% from the prior-year quarter’s reported figure.
The consensus estimate for EPS is pegged at $1.07, indicating an increase of 5.9% from the prior-year period’s reported number.
What Our Model Suggests for GE HealthCare
Per our proven model, the combination of a positive Earnings ESPand a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. That is not the case here, as you will see below.
Earnings ESP: GE HealthCare has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
GEHC’s Share Price Performance
So far this year, GE HealthCare’s shares have lost 13% compared with the industry’s 17.1% decline. The S&P 500 has gained 3.2% during the period.
Image Source: Zacks Investment Research
Stocks Worth a Look
Here are some medical product stocks worth considering as these have the right combination of elements to post an earnings beat this reporting cycle.
Henry Schein HSIC has an Earnings ESP of +0.28% and a Zacks Rank #3 at present.
HSIC’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 2.14%. The Zacks Consensus Estimate for HSIC’s first-quarter EPS indicates an improvement of 4.4% from the year-ago reported figure.
Thermo Fisher Scientific TMO has an Earnings ESP of +0.95% and a Zacks Rank of 3 at present. The company is set to release first-quarter fiscal 2026 results on April 23.
TMO’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 2.78%. The Zacks Consensus Estimate for TMO’s first-quarter EPS implies an improvement of 1% from the year-ago reported figure.
IDEXX Laboratories IDXX has an Earnings ESP of +0.77% and a Zacks Rank of 3 at present. The company is slated to release first-quarter 2026 results on May 5.
IDXX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.11%. The Zacks Consensus Estimate for IDXX’s first-quarter EPS calls for a gain 15.5% from the year-ago reported figure.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

GE HealthCare to Post Q1 Earnings: What's in Store for the Stock?

(RTTNews) - Thermo Fisher Scientific (TMO) will host a conference call at 8:30 AM ET on April 23, 2026, to discuss Q1 26 earnings results.
To access the live webcast, log on to https://ir.thermofisher.com/investors/news-events/events/default.aspx
To listen to the call, dial (833) 470-1428 (US) or +1 (646) 844-6383 (International), Access code 723173.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Thermo Fisher Scientific Q1 26 Earnings Conference Call At 8:30 AM ET

Thermo Fisher Scientific (TMO) came out with quarterly earnings of $5.44 per share, beating the Zacks Consensus Estimate of $5.2 per share. This compares to earnings of $5.15 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +4.67%. A quarter ago, it was expected that this maker of scientific instrument and laboratory supplies would post earnings of $6.43 per share when it actually produced earnings of $6.57, delivering a surprise of +2.18%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Thermo Fisher, which belongs to the Zacks Medical - Instruments industry, posted revenues of $11.01 billion for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 1.62%. This compares to year-ago revenues of $10.36 billion. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Thermo Fisher shares have lost about 11.3% since the beginning of the year versus the S&P 500's gain of 4.3%.
What's Next for Thermo Fisher?
While Thermo Fisher has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Thermo Fisher was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $5.79 on $11.47 billion in revenues for the coming quarter and $24.68 on $46.84 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Teleflex (TFX), has yet to report results for the quarter ended March 2026.
This medical equipment maker is expected to post quarterly earnings of $1.21 per share in its upcoming report, which represents a year-over-year change of -58.4%. The consensus EPS estimate for the quarter has been revised 3.7% lower over the last 30 days to the current level.
Teleflex's revenues are expected to be $533.74 million, down 23.8% from the year-ago quarter.
Should You Invest in Thermo Fisher Scientific Inc. (TMO)?
Before you invest in Thermo Fisher Scientific Inc. (TMO), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Thermo Fisher Scientific (TMO) Q1 Earnings and Revenues Top Estimates

(RTTNews) - Thermo Fisher Scientific (TMO) released earnings for its first quarter that Increases, from the same period last year
The company's earnings totaled $1.651 billion, or $4.43 per share. This compares with $1.507 billion, or $3.98 per share, last year.
Excluding items, Thermo Fisher Scientific reported adjusted earnings of $2.027 billion or $5.44 per share for the period.
The company's revenue for the period rose 6.2% to $11.005 billion from $10.364 billion last year.
Thermo Fisher Scientific earnings at a glance (GAAP) :
-Earnings: $1.651 Bln. vs. $1.507 Bln. last year. -EPS: $4.43 vs. $3.98 last year. -Revenue: $11.005 Bln vs. $10.364 Bln last year.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Thermo Fisher Scientific Q1 Profit Climbs

The following companies are expected to report earnings prior to market open on 04/23/2026. Visit our Earnings Calendar for a full list of expected earnings releases.
American Express Company (AXP)is reporting for the quarter ending March 31, 2026. The financial services company's consensus earnings per share forecast from the 8 analysts that follow the stock is $4.03. This value represents a 10.71% increase compared to the same quarter last year. AXP missed the consensus earnings per share in the 4th calendar quarter of 2025 by -0.28%. Zacks Investment Research reports that the 2026 Price to Earnings ratio for AXP is 18.81 vs. an industry ratio of 14.40, implying that they will have a higher earnings growth than their competitors in the same industry.
Thermo Fisher Scientific Inc (TMO)is reporting for the quarter ending March 31, 2026. The medical instruments company's consensus earnings per share forecast from the 8 analysts that follow the stock is $5.20. This value represents a 0.97% increase compared to the same quarter last year. In the past year TMO has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 2.18%. Zacks Investment Research reports that the 2026 Price to Earnings ratio for TMO is 21.25 vs. an industry ratio of -0.80, implying that they will have a higher earnings growth than their competitors in the same industry.
NextEra Energy, Inc. (NEE)is reporting for the quarter ending March 31, 2026. The electric power utilities company's consensus earnings per share forecast from the 5 analysts that follow the stock is $0.98. This value represents a 1.01% decrease compared to the same quarter last year. In the past year NEE has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 1.89%. Zacks Investment Research reports that the 2026 Price to Earnings ratio for NEE is 22.59 vs. an industry ratio of 17.60, implying that they will have a higher earnings growth than their competitors in the same industry.
Union Pacific Corporation (UNP)is reporting for the quarter ending March 31, 2026. The transportation (rail) company's consensus earnings per share forecast from the 7 analysts that follow the stock is $2.85. This value represents a 5.56% increase compared to the same quarter last year. Zacks Investment Research reports that the 2026 Price to Earnings ratio for UNP is 20.23 vs. an industry ratio of 16.00, implying that they will have a higher earnings growth than their competitors in the same industry.
Honeywell International Inc. (HON)is reporting for the quarter ending March 31, 2026. The diversified operations company's consensus earnings per share forecast from the 4 analysts that follow the stock is $2.31. This value represents a 7.97% decrease compared to the same quarter last year. In the past year HON has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 2.37%. Zacks Investment Research reports that the 2026 Price to Earnings ratio for HON is 21.16 vs. an industry ratio of 32.90.
Lockheed Martin Corporation (LMT)is reporting for the quarter ending March 31, 2026. The aerospace and defense company's consensus earnings per share forecast from the 7 analysts that follow the stock is $6.67. This value represents a 8.38% decrease compared to the same quarter last year. In the past year LMT has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 19.07%. Zacks Investment Research reports that the 2026 Price to Earnings ratio for LMT is 19.08 vs. an industry ratio of -62.70, implying that they will have a higher earnings growth than their competitors in the same industry.
Sanofi (SNY)is reporting for the quarter ending March 31, 2026. The large cap pharmaceutical company's consensus earnings per share forecast from the 6 analysts that follow the stock is $1.06. This value represents a 12.77% increase compared to the same quarter last year. SNY missed the consensus earnings per share in the 2nd calendar quarter of 2025 by -6.25%. Zacks Investment Research reports that the 2026 Price to Earnings ratio for SNY is 9.48 vs. an industry ratio of 15.20.
Comcast Corporation (CMCSA)is reporting for the quarter ending March 31, 2026. The cable tv company's consensus earnings per share forecast from the 8 analysts that follow the stock is $0.73. This value represents a 33.03% decrease compared to the same quarter last year. In the past year CMCSA has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 12%. Zacks Investment Research reports that the 2026 Price to Earnings ratio for CMCSA is 8.40 vs. an industry ratio of 7.60, implying that they will have a higher earnings growth than their competitors in the same industry.
Freeport-McMoran, Inc. (FCX)is reporting for the quarter ending March 31, 2026. The mining company's consensus earnings per share forecast from the 8 analysts that follow the stock is $0.47. This value represents a 95.83% increase compared to the same quarter last year. In the past year FCX has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2026 Price to Earnings ratio for FCX is 26.60 vs. an industry ratio of 12.10, implying that they will have a higher earnings growth than their competitors in the same industry.
Blackstone Inc. (BX)is reporting for the quarter ending March 31, 2026. The financial services company's consensus earnings per share forecast from the 8 analysts that follow the stock is $1.33. This value represents a 22.02% increase compared to the same quarter last year. In the past year BX has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 15.13%. Zacks Investment Research reports that the 2026 Price to Earnings ratio for BX is 20.86 vs. an industry ratio of 14.40, implying that they will have a higher earnings growth than their competitors in the same industry.
Nasdaq, Inc. (NDAQ)is reporting for the quarter ending March 31, 2026. The securities exchange company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.93. This value represents a 17.72% increase compared to the same quarter last year. In the past year NDAQ has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 5.49%. Zacks Investment Research reports that the 2026 Price to Earnings ratio for NDAQ is 22.87 vs. an industry ratio of 21.80, implying that they will have a higher earnings growth than their competitors in the same industry.
CBRE Group, Inc. (CBRE)is reporting for the quarter ending March 31, 2026. The real estate company's consensus earnings per share forecast from the 4 analysts that follow the stock is $1.13. This value represents a 31.40% increase compared to the same quarter last year. In the past year CBRE has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 2.63%. Zacks Investment Research reports that the 2026 Price to Earnings ratio for CBRE is 20.17 vs. an industry ratio of 24.50.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Thermo Fisher Scientific Inc

Sign up and unlock all the capabilities of the AI-screener